Home Cart Sign in  
Chemical Structure| 2095432-28-1 Chemical Structure| 2095432-28-1

Structure of CPI-455 HCl
CAS No.: 2095432-28-1

Chemical Structure| 2095432-28-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CPI-455 HCl is an inhibitor of KDM5. It can elevate global levels of H3K4 trimethylation (H3K4me3) and decrease the number of DTPs in multiple cancer cell line models.

Synonyms: CPI-455 HCl

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CPI-455 HCl

CAS No. :2095432-28-1
Formula : C16H15ClN4O
M.W : 314.77
SMILES Code : N#CC1=C2NC(C3=CC=CC=C3)=C(C(C)C)C(N2N=C1)=O.[H]Cl
Synonyms :
CPI-455 HCl
MDL No. :N/A
InChI Key :SNODPNXOTKXHHH-UHFFFAOYSA-N
Pubchem ID :129896721

Safety of CPI-455 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of CPI-455 HCl

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HPDLSCs 10 nM To confirm the role of H3K4me3 Regen Ther. 2022 Apr 22;20:95-106.
HEI-OC1 cells 30 µM 24 hours To investigate the protective effect of CPI-455 on HEI-OC1 cells under cisplatin-induced stress, results showed that CPI-455 reduced ROS accumulation and improved mitochondrial membrane potential and oxidative phosphorylation. Cell Mol Life Sci. 2022 Nov 17;79(12):596.
NB4 cells 5 µM 4 days CPI-455 treatment significantly induced differentiation of NB4 cells, as evidenced by increased expression of CD11b and CD11c Blood Adv. 2021 Sep 14;5(17):3241-3253.
NB4 cells 20 µM 4 days CPI-455 at 20 μM further increased the proportion of CD11b+ cells, indicating enhanced differentiation effect Blood Adv. 2021 Sep 14;5(17):3241-3253.
Eca-109 cells 15 µM 48 hours CPI-455 significantly inhibited the proliferation of Eca-109 cells and induced apoptosis by regulating the expression of related genes. World J Gastroenterol. 2021 Apr 28;27(16):1805-1815.
RAW 264.7 cells 25 µM 48 hours To verify the effect of CPI-455 on the anti-inflammatory effect of EgCF by inhibiting KDM5B, the results showed that CPI-455 treatment restored the mRNA expression of IL-6 and TNF-α, indicating that CPI-455 attenuated the anti-inflammatory effect of EgCF Parasit Vectors. 2023 Sep 9;16(1):321.
THP-1 cells 25 µM 48 hours To verify the effect of CPI-455 on the anti-inflammatory effect of EgCF by inhibiting KDM5B, the results showed that CPI-455 treatment significantly upregulated the mRNA expression of IL-6 and TNF-α, indicating that CPI-455 attenuated the anti-inflammatory effect of EgCF Parasit Vectors. 2023 Sep 9;16(1):321.
LNCaP 25 µM, 50 µM 72 hours CPI-455 attenuated androgen-induced expression of the prototypical AR target gene, KLK3/PSA, and RNA sequencing revealed that CPI-455 significantly affected the androgen-regulated transcriptome. Front Cell Dev Biol. 2023 Apr 19;11:1116424.
LNCaP:C4-2 50 µM 72 hours CPI-455 impaired androgen induction of NKX3.1 and downregulated FOXA1 expression, whereas AR expression was unchanged. Front Cell Dev Biol. 2023 Apr 19;11:1116424.
FaDu cells >50 µM 72 hours Evaluate the effects of CPI-455 alone and in combination with olaparib and cisplatin on cell viability, showing that CPI-455 significantly affects cell viability at high concentrations. Biomedicines. 2024 Jun 19;12(6):1359.
SCC-040 cells >50 µM 72 hours Evaluate the effects of CPI-455 alone and in combination with olaparib and cisplatin on cell viability, showing that CPI-455 significantly affects cell viability at high concentrations. Biomedicines. 2024 Jun 19;12(6):1359.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Cisplatin-induced ototoxicity model Intraperitoneal injection 0.5 mg/kg or 2 mg/kg Once daily for 5 days To investigate the protective effect of CPI-455 against cisplatin-induced ototoxicity in vivo, results showed that CPI-455 significantly reduced hearing loss. Cell Mol Life Sci. 2022 Nov 17;79(12):596.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.18mL

0.64mL

0.32mL

15.88mL

3.18mL

1.59mL

31.77mL

6.35mL

3.18mL

References

 

Historical Records

Categories